<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776239</url>
  </required_header>
  <id_info>
    <org_study_id>20200874</org_study_id>
    <secondary_id>1R01HL134558-01</secondary_id>
    <nct_id>NCT04776239</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)</brief_title>
  <acronym>ACESO-IHD</acronym>
  <official_title>Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells&#xD;
      (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow&#xD;
      progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">July 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR</measure>
    <time_frame>6 months (post-infusion)</time_frame>
    <description>Coronary Flow Reserve (CFR) as measured via cardiac catheterization angiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-PCI coronary artery endothelial function as assessed via FFR</measure>
    <time_frame>6 months (post infusion)</time_frame>
    <description>Fractional Flow Reserve (FFR) as measured via cardiac catheterization angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion lumen loss</measure>
    <time_frame>6 months (post-infusion)</time_frame>
    <description>Target lesion lumen loss as assessed by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Diameter Percentage (FMD%)</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>FMD% is measured via brachial artery ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPC-CFUs levels</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating angiogenic factors marker levels</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>Circulating angiogenic marker levels including Protein Kinase B, Stromal Cell Derived Factor 1 (SDF-1), Notch, Vascular Endothelial Growth Factor (VEGF) and Colony Forming Units (CFU) will be assessed from blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory markers</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>Circulating inflammatory markers including Cluster of Differentiation (CD) 3 CD 25 or CD 3 CD 69 will be assessed from blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire (SAQ) Angina Frequency</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>EQ-5D Quality of Life Questionnaire has a total score ranging from 0-10 with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Quality of life Questionnaire Overall Health Status Question</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>EQ-5D Quality of Life Questionnaire Overall Health Status question has a total score ranging from 0-100 with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF) 36 Questionnaire Quality of Life Questionnaire</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>SF 36 Quality of Life Questionnaire consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. Lower scores indicate the more disability, and higher scores indicate less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF) Questionnaire</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>IIEF is a 15 item questionnaire to be completed by males only, with scores ranging from 0-75. Higher scores indicate better male sexual function/quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Quality of Life - Females (SQOL-F) Questionnaire</measure>
    <time_frame>6 months post-infusion</time_frame>
    <description>SQOL-F Questionnaire is an 18 item questionnaire in which female participants are asked to record responses on a 6-point Likert scale (completely agree to completely disagree). Total score can range from 18 to 108. Higher scores indicate better female sexual quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)</measure>
    <time_frame>1 month post infusion</time_frame>
    <description>TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias or atrial fibrillation. TE-SAEs will be assessed by treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal MI. MACE will be assessed by treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of treatment emergent adverse event (AE) and serious adverse event (SAE) as assessed by treating physician will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal lab values</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 million Allogeneic Mesenchymal Human Stem Cells</intervention_name>
    <description>1 single intravenous infusion</description>
    <arm_group_label>Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group</arm_group_label>
    <other_name>allo-human Mesenchymal Stem Cells (hMSCs)</other_name>
    <other_name>stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered via peripheral intravenous infusion</description>
    <arm_group_label>Group 2: Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be â‰¥ 18 years of age (males and females).&#xD;
&#xD;
          2. Provide written informed consent.&#xD;
&#xD;
          3. Have a diagnosis of symptomatic ischemic heart disease (IHD) and an indication for&#xD;
             standard-of-care coronary angiography.&#xD;
&#xD;
          4. Have Diabetes Mellitus (DM) type 2 documented by glycated hemoglobin (HbA1C) &gt; 7%, or&#xD;
             on medical therapy for diabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be younger than 18 years of age.&#xD;
&#xD;
          2. Have history of prior myocardial Infarction and revascularization.&#xD;
&#xD;
          3. Have a baseline glomerular filtration rate (GFR) &lt;30 ml/min 1.73m2 estimated using the&#xD;
             Modification of Diet for Renal Disease (MDRD) formula.&#xD;
&#xD;
          4. Have poorly controlled blood glucose levels with hemoglobin A1C &gt; 8.5% in the previous&#xD;
             3 months.&#xD;
&#xD;
          5. Have a history of proliferative retinopathy or severe neuropathy requiring medical&#xD;
             treatment.&#xD;
&#xD;
          6. Have an indication for standard-of-care surgical (including valve surgery, placement&#xD;
             of left-ventricular assist device) or percutaneous intervention for the treatment of&#xD;
             valvular heart disease (including valvuloplasty).&#xD;
&#xD;
          7. Have known hypersensitivity or contraindication to aspirin; both heparin and&#xD;
             bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor);&#xD;
             or any zotarolimus, cobalt, chromium, nickel, tungsten, acrylic, or fluoropolymers; or&#xD;
             hypersensitivity to contrast media that cannot be adequately premedicated.&#xD;
&#xD;
          8. Have a hematologic abnormality as evidenced by hematocrit &lt; 25%, white blood cell &lt;&#xD;
             2,500/microliter (uL) or platelet values &lt; 100,000/uL without another explanation (per&#xD;
             investigator discretion).&#xD;
&#xD;
          9. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times&#xD;
             the upper limit of normal.&#xD;
&#xD;
         10. Have a bleeding diathesis or coagulopathy (INR &gt; 1.3), cannot be withdrawn from&#xD;
             anticoagulation therapy, or will refuse blood transfusions.&#xD;
&#xD;
         11. Be an organ transplant recipient or have a history of organ or cell transplant&#xD;
             rejection.&#xD;
&#xD;
         12. Have a clinical history of malignancy within the past 5 years (i.e., subjects with&#xD;
             prior malignancy must be disease free for 5 years), except curatively-treated basal&#xD;
             cell or squamous cell carcinoma, or cervical carcinoma.&#xD;
&#xD;
         13. Have a condition that limits lifespan to &lt; 1 year.&#xD;
&#xD;
         14. Have a history of drug or alcohol abuse within the past 24 months.&#xD;
&#xD;
         15. Be serum positive for HIV, hepatitis B surface antigen (sAg), or viremic hepatitis C.&#xD;
&#xD;
         16. Be currently participating (or participated within the previous 30 days) in an&#xD;
             investigational therapeutic or device trial.&#xD;
&#xD;
         17. Be pregnant, nursing, or of childbearing potential and not on contraceptive&#xD;
             medications. (May participate if on 2 forms of contraceptives).&#xD;
&#xD;
         18. Any other condition that in the judgment of the Investigator would be a&#xD;
             contraindication to enrollment or follow-up.&#xD;
&#xD;
         19. Coronary lesions with restenosis or heavy calcification.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio G Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauricio G Cohen, MD</last_name>
    <phone>305-243-5050</phone>
    <email>mgcohen@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvenie Desire, BA</last_name>
    <phone>305-243-7273</phone>
    <email>ydesire@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio G Cohen, MD</last_name>
      <phone>305-243-5050</phone>
      <email>mgcohen@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yvenie Desire, BA</last_name>
      <phone>305-243-7273</phone>
      <email>ydesire@miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mauricio G Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>Description: Interdisciplinary Stem Cell Institute at the University of Miami Miller School website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

